PYPD
PolyPid
NASDAQ: PYPD · HEALTHCARE · BIOTECHNOLOGY
$5.59
-3.29% today
Updated 2026-10-29
Market cap
$106.64M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$4 – $6
Volume
0.1M
WallStSmart proprietary scores
19
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-22.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →257 stocks currently score above 75
Price targets
Analyst target
$11.75
+110.20%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.29x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -22.89 — distress zone
- Thin margins at 0.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-39.52M | $-23.86M | $-29.02M | $-34.17M | $-7.85M |
| EPS | — | — | — | — | $-1.44 |
| Free cash flow | $-36.08M | $-17.43M | $-22.04M | $-28.09M | — |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
PolyPid trades at $5.59. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -22.89, it sits in the distress.
Frequently asked questions
What is PolyPid's stock price?
PolyPid (PYPD) trades at $5.59.
Is PolyPid overvalued?
PolyPid carries a Smart Value Score of 19/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of PolyPid (PYPD)?
The 12-month analyst consensus target is $11.75, about 110.2% above the current $5.59. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
PolyPid's Altman Z-Score is -22.89, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-383.02%
Beta1.38
50D MA$5.12
200D MA$4.70
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—